BURLINGAME, Calif.–(BUSINESS WIRE)–Pulse Biosciences, Inc. (Nasdaq:PLSE), a medical technology company developing a proprietary therapeutic tissue treatment platform based on Nano-Pulse Stimulation (NPS), today announced that Robert “Bob” Duggan and Maky Zanganeh, the former CEO and COO of Pharmacyclics Inc. (now Pharmacyclics LLC, a wholly owned subsidiary of AbbVie Inc.), respectively, have purchased a combined interest of 17.1% of Pulse Biosciences’ outstanding common stock of which $10 mi